In addition to its role as a prognostic indicator, the relationship between NLR and breast cancer also suggests potential therapeutic strategies targeting inflammatory pathways, such as employing IL-1β inhibition (such as canakinumab)has demonstrated promise in reducing cancer mortality, particularly in lung cancer (34). This evidence concerns the gene IL1B and breast cancer.